Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Tendera

Showing results (31-40 of 131) with videos related to

Pageof 14
Sort By:
International Journal of Molecular Medicine|July 16, 2004
The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable anginaWojciech Wojakowski, Katarzyna Maslankiewicz, Andrzej Ochala, et al.
American Heart Journal|February 17, 2019
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristicsRoberto Ferrari, Ian Ford, Kim Fox, et al.
International Journal of Cardiology|May 15, 2007
Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UKCaroline Ann Daly, Janina Stepinska, Tomasz Deptuch, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Plos One|May 10, 2012
Heart rate and use of beta-blockers in stable outpatients with coronary artery diseasePh Gabriel Steg, Roberto Ferrari, Ian Ford, et al.
Biochemical and Biophysical Research Communications|January 25, 2011
A myomesin mutation associated with hypertrophic cardiomyopathy deteriorates dimerisation propertiesRomy Siegert, Andreas Perrot, Sandro Keller, et al.
Plos One|April 28, 2015
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY RegistryLaurent Fauchier, Nicola Greenlaw, Roberto Ferrari, et al.
European Heart Journal|September 27, 2015
European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of CardiologyPerry Elliott, Philippe Charron, Juan Ramon Gimeno Blanes, et al.
Clinical Cardiology|June 1, 2017
Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery diseaseEmmanuel Sorbets, Nicola Greenlaw, Roberto Ferrari, et al.
Pageof 14

Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
International Journal of Molecular Medicine|July 16, 2004
The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable anginaWojciech Wojakowski, Katarzyna Maslankiewicz, Andrzej Ochala, et al.
American Heart Journal|February 17, 2019
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristicsRoberto Ferrari, Ian Ford, Kim Fox, et al.
International Journal of Cardiology|May 15, 2007
Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UKCaroline Ann Daly, Janina Stepinska, Tomasz Deptuch, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Plos One|May 10, 2012
Heart rate and use of beta-blockers in stable outpatients with coronary artery diseasePh Gabriel Steg, Roberto Ferrari, Ian Ford, et al.
Biochemical and Biophysical Research Communications|January 25, 2011
A myomesin mutation associated with hypertrophic cardiomyopathy deteriorates dimerisation propertiesRomy Siegert, Andreas Perrot, Sandro Keller, et al.
Plos One|April 28, 2015
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY RegistryLaurent Fauchier, Nicola Greenlaw, Roberto Ferrari, et al.
European Heart Journal|September 27, 2015
European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of CardiologyPerry Elliott, Philippe Charron, Juan Ramon Gimeno Blanes, et al.
Clinical Cardiology|June 1, 2017
Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery diseaseEmmanuel Sorbets, Nicola Greenlaw, Roberto Ferrari, et al.
Pageof 14